{"id":"https://openalex.org/W2252801432","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.7073","title":"A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer","display_name":"A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer","publication_year":2005,"publication_date":"2005-06-01","ids":{"openalex":"https://openalex.org/W2252801432","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.7073","mag":"2252801432"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2005.23.16_suppl.7073","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.7073","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.7073","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5022063365","display_name":"Giuseppe Giaccone","orcid":"https://orcid.org/0000-0002-7392-1965","observed_orcids":["https://orcid.org/0000-0002-7392-1965","https://orcid.org/0000-0002-5023-7562"]},"institutions":[{"id":"https://openalex.org/I4210131968","display_name":"The Christie Hospital","ror":"https://ror.org/03nd63441","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210131968","https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"G. Giaccone","raw_affiliation_strings":["VU Medcl Ctr, Amsterdam, The Netherlands; Inst Gustave Roussy, Paris, France; Christie Hosp NHS Trust, Manchester, United Kingdom; Roche, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU Medcl Ctr, Amsterdam, The Netherlands; Inst Gustave Roussy, Paris, France; Christie Hosp NHS Trust, Manchester, United Kingdom; Roche, Basel, Switzerland","institution_ids":["https://openalex.org/I4210131968"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111449926","display_name":"Thierry Le Chevalier","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131968","display_name":"The Christie Hospital","ror":"https://ror.org/03nd63441","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210131968","https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"T. Lechevalier","raw_affiliation_strings":["VU Medcl Ctr, Amsterdam, The Netherlands; Inst Gustave Roussy, Paris, France; Christie Hosp NHS Trust, Manchester, United Kingdom; Roche, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU Medcl Ctr, Amsterdam, The Netherlands; Inst Gustave Roussy, Paris, France; Christie Hosp NHS Trust, Manchester, United Kingdom; Roche, Basel, Switzerland","institution_ids":["https://openalex.org/I4210131968"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110052001","display_name":"N. Thatcher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131968","display_name":"The Christie Hospital","ror":"https://ror.org/03nd63441","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210131968","https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"N. Thatcher","raw_affiliation_strings":["VU Medcl Ctr, Amsterdam, The Netherlands; Inst Gustave Roussy, Paris, France; Christie Hosp NHS Trust, Manchester, United Kingdom; Roche, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU Medcl Ctr, Amsterdam, The Netherlands; Inst Gustave Roussy, Paris, France; Christie Hosp NHS Trust, Manchester, United Kingdom; Roche, Basel, Switzerland","institution_ids":["https://openalex.org/I4210131968"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016904876","display_name":"Egbert Frederik Smit","orcid":"https://orcid.org/0000-0002-7329-6995","observed_orcids":["https://orcid.org/0000-0002-7329-6995"]},"institutions":[{"id":"https://openalex.org/I4210131968","display_name":"The Christie Hospital","ror":"https://ror.org/03nd63441","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210131968","https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"E. Smit","raw_affiliation_strings":["VU Medcl Ctr, Amsterdam, The Netherlands; Inst Gustave Roussy, Paris, France; Christie Hosp NHS Trust, Manchester, United Kingdom; Roche, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU Medcl Ctr, Amsterdam, The Netherlands; Inst Gustave Roussy, Paris, France; Christie Hosp NHS Trust, Manchester, United Kingdom; Roche, Basel, Switzerland","institution_ids":["https://openalex.org/I4210131968"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042768703","display_name":"Maarten L. Janmaat","orcid":"https://orcid.org/0000-0003-4980-730X","observed_orcids":["https://orcid.org/0000-0003-4980-730X"]},"institutions":[{"id":"https://openalex.org/I4210131968","display_name":"The Christie Hospital","ror":"https://ror.org/03nd63441","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210131968","https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"M. Janmaat","raw_affiliation_strings":["VU Medcl Ctr, Amsterdam, The Netherlands; Inst Gustave Roussy, Paris, France; Christie Hosp NHS Trust, Manchester, United Kingdom; Roche, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU Medcl Ctr, Amsterdam, The Netherlands; Inst Gustave Roussy, Paris, France; Christie Hosp NHS Trust, Manchester, United Kingdom; Roche, Basel, Switzerland","institution_ids":["https://openalex.org/I4210131968"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101460329","display_name":"Javier Rodr\u00edguez","orcid":"https://orcid.org/0000-0002-5631-2981","observed_orcids":["https://orcid.org/0000-0002-5631-2981"]},"institutions":[{"id":"https://openalex.org/I4210131968","display_name":"The Christie Hospital","ror":"https://ror.org/03nd63441","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210131968","https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. Rodriguez","raw_affiliation_strings":["VU Medcl Ctr, Amsterdam, The Netherlands; Inst Gustave Roussy, Paris, France; Christie Hosp NHS Trust, Manchester, United Kingdom; Roche, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU Medcl Ctr, Amsterdam, The Netherlands; Inst Gustave Roussy, Paris, France; Christie Hosp NHS Trust, Manchester, United Kingdom; Roche, Basel, Switzerland","institution_ids":["https://openalex.org/I4210131968"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023408065","display_name":"D. Oulid-A\u00efssa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131968","display_name":"The Christie Hospital","ror":"https://ror.org/03nd63441","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210131968","https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D. Oulid-Aissa","raw_affiliation_strings":["VU Medcl Ctr, Amsterdam, The Netherlands; Inst Gustave Roussy, Paris, France; Christie Hosp NHS Trust, Manchester, United Kingdom; Roche, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU Medcl Ctr, Amsterdam, The Netherlands; Inst Gustave Roussy, Paris, France; Christie Hosp NHS Trust, Manchester, United Kingdom; Roche, Basel, Switzerland","institution_ids":["https://openalex.org/I4210131968"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021624793","display_name":"Jean\u2010Charles Soria","orcid":"https://orcid.org/0000-0001-9597-0701","observed_orcids":["https://orcid.org/0000-0001-9597-0701"]},"institutions":[{"id":"https://openalex.org/I4210131968","display_name":"The Christie Hospital","ror":"https://ror.org/03nd63441","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210131968","https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. C. Soria","raw_affiliation_strings":["VU Medcl Ctr, Amsterdam, The Netherlands; Inst Gustave Roussy, Paris, France; Christie Hosp NHS Trust, Manchester, United Kingdom; Roche, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU Medcl Ctr, Amsterdam, The Netherlands; Inst Gustave Roussy, Paris, France; Christie Hosp NHS Trust, Manchester, United Kingdom; Roche, Basel, Switzerland","institution_ids":["https://openalex.org/I4210131968"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210131968"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":28,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"23","issue":"16_suppl","first_page":"7073","last_page":"7073"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.996999979019165},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8730000257492065},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.9139999747276306},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8389999866485596},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.7839999794960022},{"id":"https://openalex.org/keywords/disease-control-rate","display_name":"disease control rate","score":0.6970000267028809},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.39500001072883606},{"id":"https://openalex.org/keywords/skin-rash","display_name":"rash","score":0.9150000214576721},{"id":"https://openalex.org/keywords/egfr-mutation","display_name":"EGFR mutation","score":0.6129999756813049},{"id":"https://openalex.org/keywords/adenocarcinoma","display_name":"adenocarcinoma","score":0.8270000219345093},{"id":"https://openalex.org/keywords/squamous-cell-carcinoma","display_name":"squamous cell carcinoma","score":0.6909999847412109},{"id":"https://openalex.org/keywords/bronchioloalveolar-carcinoma","display_name":"bronchioloalveolar carcinoma","score":0.9020000100135803},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.7490000128746033},{"id":"https://openalex.org/keywords/fdg-pet-response","display_name":"FDG-PET response","score":0.8479999899864197},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.4950000047683716},{"id":"https://openalex.org/keywords/advanced-non-small-cell-lung-cancer","display_name":"advanced non-small cell lung cancer","score":0.5009999871253967}],"concepts":[{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.9728055000305176},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9404841661453247},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.746606707572937},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6614059805870056},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5729857683181763},{"id":"https://openalex.org/C2909325608","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib Hydrochloride","level":5,"score":0.5421468019485474},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4958430230617523},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.4126036465167999},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3936294913291931},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.37078502774238586},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.36572253704071045},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3149788975715637},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.26509809494018555}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2005.23.16_suppl.7073","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.7073","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.7073","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.8799999952316284,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2007713268","https://openalex.org/W2601829225","https://openalex.org/W4291944910","https://openalex.org/W2278057905","https://openalex.org/W4234670855","https://openalex.org/W2062685921","https://openalex.org/W2287408960","https://openalex.org/W2109678955","https://openalex.org/W2595234007","https://openalex.org/W2135346764"],"abstract_inverted_index":{"7073":[0],"Background:":[1],"Erlotinib":[2,312],"(TarcevaTM)":[3],"is":[4,313,354],"an":[5],"orally":[6],"available":[7],"selective":[8],"EGFR":[9,114,291],"tyrosine-kinase":[10],"inhibitor.":[11],"In":[12],"patients":[13,48,59,87,132,144,202,253,260,284,300],"with":[14,27,49,336],"advanced":[15,50,322],"NSCLC,":[16],"2nd/3rd-line":[17],"erlotinib":[18,46,65,146,350],"significantly":[19],"prolonged":[20],"survival":[21,107],"(Shepherd":[22],"et":[23],"al.":[24],"ASCO":[25],"2004)":[26],"a":[28,126,262,331,334],"response":[29,121,183],"rate":[30,81,179],"(RR)":[31],"of":[32,43,76,82,86,91,102,128,256,349],"9%.":[33],"This":[34],"phase":[35],"II":[36],"trial":[37],"evaluated":[38],"the":[39,77,80],"efficacy":[40],"and":[41,108,116,119,147,206,224,233,250,292,315,345],"safety":[42],"1st":[44],"line":[45],"in":[47,84,125,219,225,230,234,237,298,321,327,333,342,351],"NSCLC.":[51,323],"Methods:":[52],"Chemotherapy-na\u00efve,":[53],"stage":[54],"IIIB/IV,":[55],"PS":[56,156],"0\u20132,":[57],"NSCLC":[58],"have":[60,203,208],"been":[61,209],"enrolled":[62,134],"to":[63,105,137],"receive":[64],"150":[66],"mg/day":[67],"until":[68],"disease":[69,98],"progression":[70],"or":[71,214,239,359,362],"withdrawal.":[72],"The":[73,177,243],"primary":[74],"endpoint":[75],"study":[78],"was":[79,180,280],"non-progression":[83,178],">50%":[85],"after":[88],"6":[89,212,283],"weeks":[90,124],"treatment.":[92],"Secondary":[93],"endpoints":[94],"included":[95,112],"objective":[96],"response,":[97,103],"control":[99],"rate,":[100],"duration":[101],"time":[104],"progression,":[106],"safety.":[109],"Exploratory":[110],"analyses":[111],"QoL,":[113],"expression":[115],"mutation":[117],"analysis,":[118],"FDG-PET":[120],"at":[122],"3":[123,141,222,264],"subset":[127],"patients.":[129],"Results:":[130],"54":[131],"were":[133,217,248,295,325,339],"from":[135,140],"January":[136],"July":[138],"2004":[139],"institutions.":[142],"53":[143],"received":[145],"are":[148],"assessable.":[149],"Demographics:":[150],"M/F":[151],"20/33;":[152],"median":[153],"age":[154],"61;":[155],"0/1/2":[157],"13/32/8;":[158],"pathology":[159],"adeno":[160],"23,":[161],"squamous":[162],"cell":[163,169],"9,":[164],"bronchioloalveolar":[165],"(BAC)":[166],"6,":[167],"large":[168],"8,":[170],"other":[171],"7;":[172],"smoking":[173],"status":[174],"current/former/never":[175],"10/25/18.":[176],"55%.":[181],"Best":[182],"was:":[184],"1CR,":[185],"12":[186,207],"PR,":[187],"16":[188],"SD,":[189],"17":[190],"PD,":[191],"7":[192],"NE":[193],"(RR":[194],"24.5%;":[195],"95%":[196],"CI":[197],"13.8\u201338.3).":[198],"To":[199],"date,":[200],"14":[201],"not":[204,296],"progressed":[205],"treated":[210],"for":[211,282],"months":[213],"longer.":[215],"Responses":[216,324],"observed":[218],"males":[220],"(1CR,":[221],"PR)":[223],"females":[226],"(9":[227],"PR),":[228],"mostly":[229],"adenocarcinoma":[231],"(7)":[232],"BAC":[235],"(4),":[236],"non":[238],"former":[240],"smokers":[241],"(12).":[242],"most":[244],"common":[245,341],"adverse":[246],"events":[247],"diarrhea":[249],"rash":[251],"(28":[252],"each),":[254],"primarily":[255],"grades":[257],"1/2.":[258],"Five":[259],"had":[261,308],"grade":[263,275,286,289],"event:":[265],"2":[266,288],"rash,":[267],"1":[268,270,272],"lethargy,":[269],"diarrhea,":[271],"conjunctivitis.":[273],"No":[274],"4":[276],"events.":[277],"Bilirubin":[278],"elevation":[279],"reported":[281],"(4":[285],"1,":[287],"2).":[290],"PI3K":[293],"mutations":[294],"found":[297],"15":[299],"so":[301],"far":[302],"assessed":[303],"(1":[304],"responder)":[305],"but":[306,338],"8":[307],"K-ras":[309],"mutations.":[310],"Conclusions:":[311],"active":[314],"well":[316],"tolerated":[317],"as":[318],"first-line":[319],"monotherapy":[320],"seen":[326],"both":[328],"genders":[329],"including":[330],"CR":[332],"male":[335],"adenocarcinoma,":[337],"more":[340],"women,":[343],"adenocarcinomas/BAC":[344],"non-smokers.":[346],"Further":[347],"assessment":[348],"this":[352],"setting":[353],"warranted.":[355],"Author":[356],"Disclosure":[357],"Employment":[358],"Leadership":[360],"Consultant":[361],"Advisory":[363],"Role":[364],"Stock":[365],"Ownership":[366],"Honoraria":[367],"Research":[368],"Funding":[369],"Expert":[370],"Testimony":[371],"Other":[372],"Remuneration":[373],"Roche":[374,376,378,380],"AstraZeneca,":[375,377,379]},"counts_by_year":[{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2016-06-24T00:00:00"}